On Jun 29, 2018 Zafgen Inc (NASDAQ:ZFGN) Sellers Increased Their Shorts By 13.18%

June 29, 2018 - By Clara Lewis

Zafgen, Inc. (NASDAQ:ZFGN) Corporate Logo

Change of 13.18% for Zafgen Inc (NASDAQ:ZFGN)’s shares shorted was registered. In June was issued ZFGN’s total 677,600 shares shorted by FINRA. The 598,700 previous shares are up with 13.18%. Zafgen Inc (NASDAQ:ZFGN) has 171,500 shares average volume. It’ll cost 4 days for ZFGN to restore its previous position. Zafgen Inc’s shares shorted float is 3.01%.

Ticker’s shares touched $9.98 during the last trading session after 3.96% change.Zafgen, Inc. is uptrending after having risen 60.78% since June 29, 2017. ZFGN has 539,372 volume or 114.87% up from normal. ZFGN outperformed the S&P500 by 48.21%.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity.The firm is valued at $275.08 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases.Last it reported negative earnings.

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

A total of 2 analysts rate Zafgen (NASDAQ:ZFGN) as follows: 1 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:ZFGN) has 2 ratings reports on Jun 29, 2018 according to StockzIntelligence.

For more Zafgen, Inc. (NASDAQ:ZFGN) news announced briefly go to: Nasdaq.com, Benzinga.com, Globenewswire.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher” announced on June 25, 2018, “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” on June 28, 2018, “Zafgen Announces Pricing of Offering of Common Stock” with a publish date: June 28, 2018, “Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to …” and the last “Zafgen Announces Proposed Offering of Common Stock” with publication date: June 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.